Isogenic hiPSC-CMs modeling HCM with the E99K-ACTC1 mutation demonstrate arrhythmogenesis that can be effectively rescued with dual dantrolene/ranolazine treatment, highlighting the role of genetic background and age in phenotypic expression.
Answers are grounded in this paper and cite their sources.
hiPSC-CM models of E99K-ACTC1 HCM demonstrate arrhythmogenesis; hypothesis-generating for mechanism-based therapies, pending clinical validation.
Hypertrophic cardiomyopathy (HCM) is a primary disorder of contractility in heart muscle. To gain mechanistic insight and guide pharmacological rescue, this study models HCM using isogenic pairs of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) carrying the E99K-ACTC1 cardiac actin mutation. In both 3D engineered heart tissues and 2D monolayers, arrhythmogenesis was evident in all E99K-ACTC1 hiPSC-CMs. Aberrant phenotypes were most common in hiPSC-CMs produced from the heterozygote father. Unexpectedly, pathological phenotypes were less evident in E99K-expressing hiPSC-CMs from the two sons. Mechanistic insight from Ca 2+ handling expression studies prompted pharmacological rescue experiments, wherein dual dantroline/ranolazine treatment was most effective. Our data are consistent with E99K mutant protein being a central cause of HCM but the three-way interaction between the primary genetic lesion, background (epi)genetics, and donor patient age may influence the pathogenic phenotype. This illustrates the value of isogenic hiPSC-CMs in genotype-phenotype correlations.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: